Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships.

Grass P, Marbach P, Bruns C, Lancranjan I

Metabolism: clinical and experimental1 Aug 1996Cited by 53 (Europe PMC)

PMID8769375DOI10.1016/s0026-0495(96)90075-xPepBankPUB-08769375

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialPharmacokinetics
In acromegalic patients, Sandostatin LAR injections every 4 weeks produced broadly constant octreotide concentrations with dose proportionality.
In plain wordsIn acromegalic patients, Sandostatin LAR produced broadly constant drug concentrations that increased with dose.
Peptide
Octreotide
Outcome
Not applicableOctreotide concentrations
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10, 20, and 30 mg · intramuscularAs given in this study (human).
Source sentences
Summary
These produced broadly constant octreotide concentrations with dose proportionality.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind, single-dose studies of 120 acromegalic patients given 10, 20, and 30 mg Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland) established the drug's pharmacokinetic profile.
Summary · context
Patients then entered open-labeled extension phases, with Sandostatin LAR intramuscular (IM) injections every 4 weeks.
Report a problemFND-0876937501
02HumanNon-randomized trialPharmacokinetics
In acromegalic patients receiving Sandostatin LAR, area fluctuations were minimal.
In plain wordsIn acromegalic patients receiving Sandostatin LAR, area fluctuations were minimal.
Peptide
Octreotide
Outcome
Not applicableArea fluctuations
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10, 20, and 30 mg · intramuscularAs given in this study (human).
Source sentences
Summary
Area fluctuations were minimal.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind, single-dose studies of 120 acromegalic patients given 10, 20, and 30 mg Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland) established the drug's pharmacokinetic profile.
Summary · context
Patients then entered open-labeled extension phases, with Sandostatin LAR intramuscular (IM) injections every 4 weeks.
Report a problemFND-0876937502
03HumanNon-randomized trialPharmacokinetics
In acromegalic patients receiving Sandostatin LAR, steady state generally occurred after the second to third injection.
In plain wordsIn acromegalic patients, Sandostatin LAR generally reached steady drug levels after the second to third injection.
Peptide
Octreotide
Outcome
Not applicableSteady state
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10, 20, and 30 mg · intramuscularAs given in this study (human).
Measurements
Injections needed to reach steady state
2 to 3 injections
Sandostatin LAR every 4 weeks; generally
Source sentences
Summary
Steady-state conditions were generally reached after the second to third injection.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind, single-dose studies of 120 acromegalic patients given 10, 20, and 30 mg Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland) established the drug's pharmacokinetic profile.
Summary · context
Patients then entered open-labeled extension phases, with Sandostatin LAR intramuscular (IM) injections every 4 weeks.
Report a problemFND-0876937503
04HumanNon-randomized trialMechanism
In acromegalic patients, Sandostatin LAR showed no evidence of downregulation over 1 year.
In plain wordsIn acromegalic patients, Sandostatin LAR showed no evidence of downregulation over 1 year.
Peptide
Octreotide
Outcome
No significant changeDownregulation
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
10, 20, and 30 mg · intramuscular · 1 yearAs given in this study (human).
Source sentences
Summary
There was no evidence of downregulation with Sandostatin LAR over 1 year of study.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind, single-dose studies of 120 acromegalic patients given 10, 20, and 30 mg Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland) established the drug's pharmacokinetic profile.
Summary · context
Patients then entered open-labeled extension phases, with Sandostatin LAR intramuscular (IM) injections every 4 weeks.
Report a problemFND-0876937504
05HumanNon-randomized trialEfficacy outcome
In acromegalic patients, based on the pharmacokinetic/pharmacodynamic relationship of octreotide, a starting dose of 20 mg Sandostatin LAR every 4 weeks provides GH control comparable to the thrice-daily subcutaneous regimen, commonly 0.3 to 0.6 mg/d.
In plain wordsIn acromegalic patients, drug-level and hormone-response data suggest Sandostatin LAR every 4 weeks gives GH control comparable to thrice-daily subcutaneous octreotide.
Peptide
Octreotide
Outcome
Direction not reportedGH control
Study
n: not reported in source
Comparator
Thrice-daily subcutaneous octreotide, commonly 0.3 to 0.6 mg/d
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg every 4 weeks · intramuscularAs given in this study (human).
Source sentences
Summary
Based on the pharmacokinetic/pharmacodynamic relationship of octreotide, a starting dose of 20 mg Sandostatin LAR and administrations every 4 weeks provide growth hormone (GH) control comparable to the thrice-daily subcutaneous (SC) injection regimen, which is commonly 0.3 to 0.6 mg/d.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind, single-dose studies of 120 acromegalic patients given 10, 20, and 30 mg Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland) established the drug's pharmacokinetic profile.
Summary · context
Patients then entered open-labeled extension phases, with Sandostatin LAR intramuscular (IM) injections every 4 weeks.
Report a problemFND-0876937505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.